Prophylactic replacement therapy has become the standard treatment for severe hemophilia A. It consists of regular injections of FVIII concentrate and aims at preventing spontaneous joint bleeds by achieving a trough FVIII activity greater than 0.01 IU/mL [4, 5]. The gene discussed is F8; the disease is hemophilia A.